Dade Behring gets warning letter from FDA
This article was originally published in Clinica
Executive Summary
The FDA has accused Dade Behring of failing to take corrective action over problems with preservatives which had resulted in the withdrawal of three loads of Chlamydia test kits. In addition, the FDA says in a warning letter to Dade Behring, the company was slow at processing complaints and problems were found with the sampling plan for reliability testing.